Jaguar Animal Health Inc (JAGX) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Jaguar Animal Health Inc (JAGX) has a cash flow conversion efficiency ratio of -1.085x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-5.34 Million) by net assets ($4.92 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see Jaguar Animal Health Inc market cap and net worth for the company's overall valuation and market capitalisation.
Jaguar Animal Health Inc - Cash Flow Conversion Efficiency Trend (2007–2025)
This chart illustrates how Jaguar Animal Health Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Jaguar Animal Health Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Jaguar Animal Health Inc ranked by their cash flow conversion efficiency. Explore JAGX cash flow quality index to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Cariboo Rose Resources Ltd
V:CRB
|
0.014x |
|
Filament Health Corp
NEO:FH
|
-0.228x |
|
Midwich Group PLC
LSE:MIDW
|
0.268x |
|
TECIL Chemicals and Hydro Power Limited
NSE:TECILCHEM
|
N/A |
|
Prominence Energy Ltd
AU:PRM
|
-0.075x |
|
Altech Batteries Ltd
AU:ATC
|
-0.199x |
|
KINGS ENTERTAINMENT GROUP
F:L12
|
N/A |
|
Prostemics Co. Ltd
KQ:203690
|
-0.036x |
Annual Cash Flow Conversion Efficiency for Jaguar Animal Health Inc (2007–2025)
The table below shows the annual cash flow conversion efficiency of Jaguar Animal Health Inc from 2007 to 2025. View Jaguar Animal Health Inc stock quote for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $-18.69 Million | $5.80 Million | -0.310x | +93.14% |
| 2024-12-31 | $6.49 Million | $-29.38 Million | -4.525x | +33.34% |
| 2023-12-31 | $4.90 Million | $-33.24 Million | -6.788x | -127.81% |
| 2022-12-31 | $-1.36 Million | $-33.10 Million | 24.413x | +927.47% |
| 2021-12-31 | $11.85 Million | $-34.97 Million | -2.950x | -232.18% |
| 2020-12-31 | $17.20 Million | $-15.28 Million | -0.888x | +53.66% |
| 2019-12-31 | $10.67 Million | $-20.46 Million | -1.917x | +54.61% |
| 2018-12-31 | $5.38 Million | $-22.73 Million | -4.223x | -641.85% |
| 2017-12-31 | $17.26 Million | $-9.82 Million | -0.569x | -109.69% |
| 2016-12-31 | $-2.45 Million | $-14.41 Million | 5.873x | +280.47% |
| 2015-12-31 | $4.40 Million | $-14.32 Million | -3.254x | +34.70% |
| 2014-12-31 | $1.10 Million | $-5.46 Million | -4.984x | -46.54% |
| 2007-12-31 | $5.40 Million | $-18.37 Million | -3.401x | -- |
About Jaguar Animal Health Inc
Jaguar Health, Inc., a commercial-stage pharmaceuticals company, focuses on developing plant-based prescription medicines for people and animals with gastrointestinal distress. It operates through two segments, Animal Health and Human Health. The company focuses on developing and commercializing prescription and non-prescription products for companion and production animals; and human products. I… Read more